Skip to main content
Premium Trial:

Request an Annual Quote

Dx Shop Upstream Biosciences Inks Option to Acquire Pacific Pharma

NEW YORK (GenomeWeb News) – Upstream Biosciences yesterday said it has signed an option to buy Pacific Pharma Technologies, a company focused on drug development for parasitic diseases.
Upstream Biosciences, which develops genetic diagnostics for cancer and for predicting drug responses, said the agreement gives it an exclusive 3-month option to negotiate terms of the acquisition.
Pacific Pharma owns technologies “relating to certain widespread infectious diseases,” and is researching the potential of expanding the application of its IP for cancer treatment, Upstream said.
Both companies are located in Vancouver, BC.
Pacific Pharma has ongoing projects through the University of British Columbia related to its parasite studies of Leishmaniasis and for Trypanosomiasis. These protozoan species are related to pathogens that cause malaria and Chagas disease.
Upstream Biosciences said it is currently developing diagnostic biomarkers for cancers of the liver, prostate, ovaries, and thyroid.
In recent weeks, Upstream Biosciences said it has secured CA$2 million ($1.72 million) in equity financing and eliminated CA$800,000 in debt, according to the company's web site.                                                                                                                 

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.